@entity1311 and @entity900 chemotherapy for metastatic XXXX after failure of two courses of @entity902 -based regimens.

@entity1 @entity632 @entity900 @entity1311 @entity189 @entity136 @entity1398 @entity1499 @entity902 @entity5713
OBJECTIVES: We investigated the outcomes of @entity1311 and @entity900 chemotherapy as an optional regimen for @entity1 with metastatic @entity189 after failure of two consecutive @entity902 -based regimens. METHODS: We retrospectively analyzed the data of 21 @entity1 who had evidence of disease progression after two consecutive @entity902 -based regimens, @entity136 and @entity900 (GC course), and @entity1499 , @entity5713 , @entity632 and @entity900 (M-VAC course) as first-line and second-line treatments. As third-line chemotherapy, @entity1 received @entity1311 (175 mg/m(2)) and @entity900 (70 mg/m(2)) every 3 weeks until disease progression. RESULTS: Complete remission occurred in one @entity1 (4.8%), partial remission occurred in three @entity1 (14.3%) and stable disease occurred in five @entity1 (23.8%). The overall response rate was 19.0% and the overall disease control rate, including stable disease, was 42.9%. The median progression-free survival (PFS) was 3 months (95% CI 3.0-5.0). The median overall survival was 9 months (95% CI 7.0-15.0). Grade 3 to 4 @entity1398 appeared in 85.7% of @entity1 . No life-threatening complications were observed. CONCLUSIONS: @entity1311 and @entity900 chemotherapy could be an optional regimen for @entity1 with metastatic @entity189 after the failure of two consecutive standard @entity902 -based regimens.
